94459-87-7

Upstream product

• 90537-40-9 2-ethoxy-5-nitrobenzoyl chloride 
• 100-46-9 benzylamine 
• 57148-23-9 2-ethoxy-5-nitro-benzoic acid 
• 80074-34-6 2-ethoxy-5-nitro-benzoic acid methyl ester 

Relevant academic research and scientific papers

The discovery of novel, potent ERR-alpha inverse agonists for the treatment of triple negative breast cancer

The estrogen-related receptor α (ERRα) is an orphan receptor and a novel target for solid tumor therapy, conceivably through effects on the regulation of tumor cell energy metabolism associated with energy stress within solid tumor micro environments. Here we describe the discovery of novel potent inverse agonists of ERRα. In?vitro, compound 11 potently inhibits ERRα’s transcriptional activity by preventing endogenous PGC-1α and ERRα binding and suppresses the proliferation of different human cancer cell lines and the migration of breast cancer cells (MDA-MB-231). In?vivo, compound 11 demonstrates a strong inhibitory effect on the growth of human breast cancer xenografts (MDA-MB-231) and the tumor growth is inhibited by 40.9% after treating with compound 11 (30?mg/kg). The binding mode shows that compound 11 interacts with the binding pocket of ERRα through hydrogen interactions with the residue Gly397 and hydrophobic interactions with the hydrophobic residues. All these results suggest that compound 11 represents a novel potent ERRα inverse agonist and is promising in the discovery of antitumor compounds for the treatment of triple negative breast cancer.

A N - benzyltin -5 - [3 - (2, 5 - diethoxy -4 - mesyl - benzyl) - ureido] -2 - ethoxy methyl amide new compound, preparation method and use (by machine translation)

The present invention provides a new compound, the compound is benzyl N - the name of the -5 - [3 - (2, 5 - diethoxy -4 - mesyl - benzyl) - ureido] -2 - ethoxy methyl amide, the molecular weight of this compound 584.6, the structure of the compound (compound 1), see structural formula of; at the same time, the invention provides the compound 1 method for the preparation of; the present invention provides compound has very good resistance to the class of, can be used for new drug studies, in particular II type diabetes of innovative pharmaceutical research field. (by machine translation)